21st
21st Annual Meeting of the Japanese Society of Clinical Neuropsychopharmacology
jointly with 41th Annual Meeting of Japanese Society of Newropsychopharmacology
October 27-29, 2011
KEIO PLAZA HOTEL , Tokyo, Japan
| FIRST AUTHOR INDEX | |||
|---|---|---|---|
| First Name | Last Name | No. | Title |
| Nestler | Eric J. | SL1 | New insight into the neurobiology of depression |
| Papakostas | George I. | SL3 | Predictors, moderators, and mediators of treatment outcome in major depressive disorder |
| Barnes | Thomas R | CL-1 | Antipsychotic-induced akathisia and its assessment |
| UCHIDA | HIROYUKI | S1-4 | Tips on how to publish your data in English |
| UCHIDA | HIROYUKI | S4-4 | Individually tailored antipsychotic treatment for schizophrenia: evidence and hypothesis |
| MATSUZAKI | HIDEO | S5-1 | A perspective of biological marker research for autism |
| YAMASUE | HIDENORI | S5-4 | Neural basis of atypical social behavior in people with autism |
| SUZUKI | KATSUAKI | S5-5 | Positron emission tomography imaging studies in autism spectrum disorders |
| Lin | Ching-Hua | S8-1 | Early prediction of psychotropic response |
| Choi | Sung-Ku | S8-2 | Cns drug trials in Asia – Current trend and future |
| Mei | Si Tian | S8-3 | Psychopharmacological clinical trials and researches in China |
| Tateishi | Tomonori | S8-4 | Regulatory perspective on current and future drug developments in psychiatric and neurological diseases in Japan |
| OTSUKI | KOJI | S12-1 | Epigenetic regulation in depression |
| Yamada | Makiko | S17-2 | Neuroimaging of psychiatric symptoms |
| TAKAHASHI | HIDEHIKO | S17-3 | Toward a molecular understanding of altered decision-making in neuropsychiatric disorders |
| HIROI | NOBORU | SS-2 | Genetic mouse model of developmental neuropsychiatric disorders |
| Takeuchi | Katsuya | AB | Overseas Training Report |
| Papakostas | George I. | LS2-1 | Management of Treatment-Resistant Major Depressive Disorder |
| Taylor | David | LS2-4 | Aripiprazole and the maudsley guidelines – a drug for all seasons? |
| Montejo | Angel L. | LS3-2 | Achieving remission preserving quality of life and sexual relationships in depression |
| Barnes | Thomas R | ES2-3 | Improving the quality of prescribing practice in psychiatry: the work of the Prescribing Observatory for Mental Health (POMH-UK) |
| YOSHIDA | TAKAYUKI | O2-F2 | Functional molecular bases of the amygdaloid synaptic transmission involved in extinction of fear memory |
| OHMURA | YU | O2-F4 | Lithium has suppressing effects on impulsive-like action independent of its anorexic effects |
| MIYOSHI | KO | O3-G8 | The neuronal primary cilium, a putative extra-synaptic neurotransmission device, expresses dopamine receptors |
| YOSHIMURA | REIJI | O3-I2 | Aripiprazole altered plasma levels of brain-derived neurotrophic factor, and catecholamine metabolites in fi rst-episode untreated Japanese schizophrenia patients |
| OHNISHI | YOSHINORI | P1-C1 | Differential role of deltaFosB and delta2deltaFosB in response to stress and drugs of abuse |
| OHNISHI | YOKO | P1-C2 | Screening and Identifi cation of protein binding partners of deltaFosB using yeast two hybrid system |
| Goto | Naoki | P1-DⅠ5 | No alterations of brain GABA after 6 months of treatment with atypical antipsychotic drugs in early-stage fi rst-episode schizophrenia |
| KOIDE | TAKAYOSHI | P1-DⅠ6 | Evaluation of factors affecting Continuous Performance Test Identical Pairs Version (CPT-IP) score of schizophrenic patients in a Japanese clinical Sample |
| WATANABE | SHINYA | P1-DⅡ2 | Association study of Fat-mass and obesity-associated (FTO) gene and body mass index in a Japanese schizophrenia and healthy Japanese population |
| OHI | KAZUTAKA | P1-DⅡ6 | The KCNH2 gene is associated with neurocognition and the risk of Schizophrenia |
| Hashimoto | Ryota | P1-DⅢ1 | RELA Gene is associated with risk for schizophrenia and defi cits in prepulse Inhibition |
| NAKATAKI | MASAHITO | P1-DⅢ5 | Amino acid neurotransmission in schizophrenia patients and the effects of antipsychotic medication: A proton magnetic resonance spectroscopy study |
| ISHITOBI | MAKOTO | P1-DⅥ2 | Adjunctive treatment with low-dosage pramipexole for risperidoneinduced hyperprolactinemia and sexual dysfunction in a male patient with schizophrenia |
| UTSUNOMIYA | KENSUKE | P1-KⅠ1 | Association analysis between the 1,alpha-Hydroxylase (CYP27B1) gene polymorphisms and late-onset Alzheimer’s disease |
| NAKATANI | YOSHIHIKO | P2-AⅡ1 | The effect of corticosterone to immunoreactive cell lines |
| Yun | Jaesuk | P2-AⅡ4 | Npas4 regulates neurite outgrowth and phosphoryation of synapsin I |
| MORIGUCHI | SHIGEKI | P2-BⅡ1 | Reduced calcium/calmodulin-dependent protein kinase II activity in the hippocampus is associated with impaired cognitive function in 1-metyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice |
| EZUMI | SATORU | P2-BⅡ2 | Difference in the effect of Imipramine and GBR12909 on the Runway method using priming stimulation effect (PSE) of the intracranial selfstimulation (ICSS) behavior |
| UCHIDA | HIROYUKI | P2-GⅥ1 | Predicting antipsychotic plasma concentrations before titrating the dose: a population pharmacokinetic study |
| TSUTSUMI | CHISA | P2-GⅥ4 | The evolution of antipsychotic switch and polypharmacy in natural practice – a longitudinal perspective |
| KUROIWA | MAHOMI | P2-HⅢ3 | Effect of chronic fl uoxetine treatment on dopamine D1 receptor signaling in the hippocampal dentate gyrus |
| IGA | JUNICHI | P2-IⅢ3 | SOCS3, a candidate gene for the molecular effects of lithium and pathophysiology of MDD |